What do the regulatory classifications mean, and why do they change my investor list?

Put a founder building a sleep-tracking app and a founder building an implantable cardiac device in the same room and you have two people who will accurately describe themselves as health tech. They will attend the same conferences and appear on the same government programme lists. If they work from the same investor spreadsheet, one of them is wasting a quarter.

Founders sort investors by sector. Investors sort founders by how long until this is a product. Only the second sorting decides whether you get a cheque.

The five routes

Drug or biologic. Preclinical work, then Phase I, II and III trials, then a submission to Health Canada or the US Food and Drug Administration. The longest and most capital-hungry path, needing investors who are structurally able to wait a decade — a property of their fund, not of their enthusiasm.

Medical device, lower risk. Health Canada sorts devices into Classes I to IV; the US FDA uses I to III, so the numbers do not line up between the two countries, which has caused more confusion in more pitch meetings than anyone would like. Class I and II covers most instruments, wearables and imaging hardware. In the US these usually reach market by demonstrating equivalence to an existing device — the 510(k) route. Months to a couple of years, not a decade.

Medical device, higher risk. Class III and IV in Canada, roughly Class III in the US: implants, anything life-sustaining, anything carrying real risk if it fails. Clinical evidence is required, and in the US the route is usually Premarket Approval rather than 510(k). The timelines and budgets look closer to a drug than to a wearable, which is exactly why treating "medical devices" as one category misleads.

Diagnostics. In-vitro diagnostics and lab tests, with their own evidence requirements and, in the US, a possible laboratory-developed-test route.

Software. Some digital health is regulated as Software as a Medical Device; some wellness and workflow software is not regulated at all. The gap between those two is large, and it matters to investors as much as to regulators.

Why this quietly ruins your outreach

A great many health-tech and digital-health funds state plainly, in public, on their own websites, that they will not fund anything facing years of clinical work. They are not being coy — they have a fund life, and a Class IV implant does not fit inside it.

So when a Class IV founder emails forty "health tech investors," a large share of those emails were never going to work, not because the pitch was weak but because the fund's structure made yes impossible before the founder hit send. The rejections come back polite and non-specific, which is the cruellest version: you learn nothing, and you conclude the problem is your deck.

The reverse is just as expensive. A workflow-software founder pitching deep life-science funds gets passed on for being too shallow — not enough defensibility, not enough regulatory moat. Same mismatch, opposite direction.

The more useful question

Instead of "who invests in health tech in Canada," ask: who has funded something on my regulatory pathway, at my stage, in the last two years? Harder to answer, which is why it is worth answering. It also shortens your list dramatically, and a short list that can say yes beats a long one that cannot.

Sorting on pathway rather than sector label is what stops a roadmap filling with names that were never going to fund you. It is a tracked dimension on every one of our 159 verified investors.

This is background to help you read your roadmap, not regulatory advice. If you are unsure which class you fall into, describe what your product does in your own words at intake and we will flag it rather than guess.